Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174265
Status:
COMPLETED
Last Update Posted:
2022-02-09
First Post:
2005-09-09
Brief Title:
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial A7501014COMPLETEDP05772
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Multicenter Double-Blind Flexible-Dose 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an extension study of A7501013 P05771NCT00145496 to further test
the efficacy and safety of Asenapine compared with a
marketed agent olanzapine in the treatment of patients with
persistent negative symptoms of schizophrenia
the efficacy and safety of Asenapine compared with a
marketed agent olanzapine in the treatment of patients with
persistent negative symptoms of schizophrenia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Aphrodite | None | None | None |
| A7501014 | None | None | None |